Remetinostat

Drug Profile

Remetinostat

Alternative Names: SHAPE; SHP-141; SHP-141C; Suberohydroxamic acid phenyl ester (SHAPE)

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Medivir AB; Shape Pharmaceuticals
  • Class Antineoplastics; Benzoic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous T cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 02 Jan 2017 Chemical structure information added
  • 29 Dec 2016 Medivir acquires remetinostat from TetraLogic
  • 09 Dec 2016 SHP 141 is now called remetinostat
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top